-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Sulfadoxine
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2447-57-6.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2447-57-6 |
| Description | Sulfadoxine is an ultra-long-lasting sulfonamide with an IC50 of 249 μg/ml for P. vivax. Sulfadoxine is an ultra-long-lasting sulfonamide previously used in combination with pyrimethamine to treat or prevent malaria. Due to high levels of resistance, its use is no longer recommended routinely. |
Product Information
| Synonyms | WR-4873; WR4873; WR 4873; Solfadossina; Sulforthomidine |
| IUPAC Name | 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide |
| Molecular Weight | 310.33 |
| Molecular Formula | C12H14N4O4S |
| Canonical SMILES | COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N |
| InChI | InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16) |
| InChIKey | PJSFRIWCGOHTNF-UHFFFAOYSA-N |
| Boiling Point | 522.8°C at 760 mmHg |
| Melting Point | 197°C |
| Flash Point | 270.0±32.9 °C |
| Purity | >98% |
| Density | 1.441 g/cm3 |
| Solubility | Soluble in Water |
| Appearance | White to Off-white Solid |
| Application | Antimalarials |
| Storage | Store at -20°C |
| Complexity | 420 |
| Exact Mass | 310.07357611 |
| Index Of Refraction | 1.623 |
| In Vitro | Sulfadoxine(Sulphadoxine) is an ultra-long-lasting sulfonamide. Sulfadoxine is often used in combination with pyrimethamine to treat or prevent malaria. Both drugs are antifolates; they inhibit the production of enzymes involved in the synthesis of folic acid within the parasites. Either drug by itself is only moderately effective in treating malaria, because the parasite Plasmodium falciparum may be able to use exogenous folic acid, i.e. folic acid which is present in the parasite's environment, while in combination, the two substances have a synergistic effect which outbalances that ability. |
| PSA | 124.81000 |
| Target | Parasite; HIV; Antibiotic |
| Vapor Pressure | 0.0±1.4 mmHg at 25°C |
| XLogP3-AA | 0.7 |
